Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.47 Million CHF | -93.18% |
| 2022 | 21.68 Million CHF | -19.67% |
| 2021 | 26.99 Million CHF | -54.85% |
| 2020 | 59.8 Million CHF | 1.39% |
| 2019 | 58.98 Million CHF | 8.09% |
| 2018 | 54.56 Million CHF | 2.75% |
| 2017 | 53.11 Million CHF | 0.0% |
| 2016 | - CHF | 0.0% |
| 2015 | - CHF | 0.0% |
| 2014 | - CHF | 0.0% |
| 2013 | - CHF | -100.0% |
| 2012 | 2.17 Million CHF | -1.63% |
| 2011 | 2.2 Million CHF | -1.52% |
| 2010 | 2.24 Million CHF | 0.0% |
| 2009 | - CHF | 0.0% |
| 2008 | - CHF | 0.0% |
| 2007 | - CHF | -100.0% |
| 2006 | 931 Thousand CHF | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - CHF | 0.0% |
| 2024 Q2 | 845 Thousand CHF | 0.0% |
| 2023 Q4 | 1.47 Million CHF | 4122.86% |
| 2023 FY | 1.47 Million CHF | -93.18% |
| 2023 Q1 | 19.52 Million CHF | -9.99% |
| 2023 Q3 | 35 Thousand CHF | -99.82% |
| 2023 Q2 | 19.52 Million CHF | 0.0% |
| 2022 Q3 | 21.68 Million CHF | -15.98% |
| 2022 FY | 21.68 Million CHF | -19.67% |
| 2022 Q4 | 21.68 Million CHF | 0.0% |
| 2022 Q1 | 25.81 Million CHF | -4.4% |
| 2022 Q2 | 25.81 Million CHF | 0.0% |
| 2021 Q2 | 16.4 Million CHF | 0.0% |
| 2021 FY | 26.99 Million CHF | -54.85% |
| 2021 Q4 | 26.99 Million CHF | 0.0% |
| 2021 Q3 | 26.99 Million CHF | 64.54% |
| 2021 Q1 | 16.4 Million CHF | -72.56% |
| 2020 Q2 | 59.5 Million CHF | 0.0% |
| 2020 Q1 | 59.5 Million CHF | 0.89% |
| 2020 FY | 59.8 Million CHF | 1.39% |
| 2020 Q4 | 59.8 Million CHF | 0.0% |
| 2020 Q3 | 59.8 Million CHF | 0.5% |
| 2019 Q2 | 58.26 Million CHF | 0.0% |
| 2019 Q3 | 58.98 Million CHF | 1.22% |
| 2019 FY | 58.98 Million CHF | 8.09% |
| 2019 Q4 | 58.98 Million CHF | 0.0% |
| 2019 Q1 | 58.26 Million CHF | 6.78% |
| 2018 Q2 | 53.82 Million CHF | 0.0% |
| 2018 Q1 | 53.82 Million CHF | 1.34% |
| 2018 Q4 | 54.56 Million CHF | 0.69% |
| 2018 Q3 | 54.19 Million CHF | 0.68% |
| 2018 FY | 54.56 Million CHF | 2.75% |
| 2017 Q2 | 52.42 Million CHF | 0.0% |
| 2017 Q1 | 52.42 Million CHF | 0.0% |
| 2017 Q4 | 53.11 Million CHF | 0.0% |
| 2017 FY | 53.11 Million CHF | 0.0% |
| 2016 Q1 | - CHF | 0.0% |
| 2016 Q3 | - CHF | 0.0% |
| 2016 Q4 | - CHF | 0.0% |
| 2016 Q2 | - CHF | 0.0% |
| 2016 FY | - CHF | 0.0% |
| 2015 FY | - CHF | 0.0% |
| 2015 Q1 | - CHF | 0.0% |
| 2015 Q2 | - CHF | 0.0% |
| 2015 Q3 | - CHF | 0.0% |
| 2015 Q4 | - CHF | 0.0% |
| 2014 Q3 | - CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | - CHF | 0.0% |
| 2014 Q4 | - CHF | 0.0% |
| 2014 Q2 | - CHF | 0.0% |
| 2013 Q4 | - CHF | 0.0% |
| 2013 Q3 | - CHF | 0.0% |
| 2013 Q2 | - CHF | 0.0% |
| 2013 Q1 | - CHF | -100.0% |
| 2013 FY | - CHF | -100.0% |
| 2012 Q2 | 2.18 Million CHF | 0.0% |
| 2012 Q3 | - CHF | -100.0% |
| 2012 Q4 | 2.17 Million CHF | 0.0% |
| 2012 FY | 2.17 Million CHF | -1.63% |
| 2011 Q4 | 2.2 Million CHF | 0.0% |
| 2011 FY | 2.2 Million CHF | -1.52% |
| 2011 Q2 | 2.22 Million CHF | 0.0% |
| 2010 FY | 2.24 Million CHF | 0.0% |
| 2010 Q2 | 2.25 Million CHF | 0.0% |
| 2010 Q4 | 2.24 Million CHF | 0.0% |
| 2009 FY | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2008 FY | - CHF | 0.0% |
| 2007 FY | - CHF | -100.0% |
| 2006 FY | 931 Thousand CHF | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Addex Therapeutics Ltd | 70.38 Thousand CHF | -2000.028% |
| BB Biotech AG | 304.9 Million CHF | 99.515% |
| Basilea Pharmaceutica AG | 95.45 Million CHF | 98.452% |
| Evolva Holding SA | - CHF | -Infinity% |
| Idorsia Ltd | 931 Million CHF | 99.841% |
| Kuros Biosciences AG | 1.56 Million CHF | 5.559% |
| Molecular Partners AG | 2.44 Million CHF | 39.525% |
| Relief Therapeutics Holding AG | 9000.00 CHF | -16322.222% |